Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update
Hims & Hers Health closed at $44.39 on Nov. 3, down 2.3%, then jumped to about $46.70 in after-hours trading after Q3 revenue beat estimates. Revenue rose 49% to $599 million, but adjusted EPS missed consensus. Subscribers reached 2.47 million, up 21% year-over-year. The company said it is in talks with Novo Nordisk to offer a new obesity pill, pending approval.